MeSH D001168 - arthritis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D007592:Joint diseases
D001168:Â
Arthritis
D001169:Experimental arthritis
0 Companies
0 Drugs
Success rate
D001170:Infectious arthritis
D001171:Juvenile arthritis
D001172:Rheumatoid arthritis
D002805:Chondrocalcinosis
0 Companies
0 Drugs
Success rate
D006073:Gout
D010003:Osteoarthritis
D010489:Periarthritis
0 Companies
0 Drugs
Success rate
D012213:Rheumatic fever
D015535:Psoriatic arthritis
D025241:Spondylarthritis
D058566:Sacroiliitis
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Roche | Tocilizumab | RoActemra |  | 2009-01-15 |  |  |
| Sandoz | Etanercept | Erelzi |  | 2017-06-23 |  |  |
| Adalimumab | Halimatoz |  | 2018-07-26 |  |  | |
| Adalimumab | Hefiya |  | 2018-07-26 |  |  | |
| Adalimumab | Hyrimoz |  | 2018-07-26 |  |  | |
| Boehringer Ingelheim | Adalimumab | Cyltezo |  | 2017-11-10 |  |  |
| AbbVie | Adalimumab | Humira |  | 2003-09-08 | $13,133 M | Q2/23-Q1/24 |
| Pfizer | Adalimumab | Amsparity |  | 2020-02-13 |  |  |
| Etanercept | Enbrel |  | 2000-02-02 | $830 M | Y2023 | |
| Bristol Myers Squibb | Abatacept | Orencia |  | 2007-05-21 | $3,635 M | Q2/23-Q1/24 |
| Celltrion | Adalimumab | Yuflyma |  | 2021-02-11 |  |  |
| Fresenius Kabi | Adalimumab | Idacio |  | 2019-04-02 |  |  |
| Adalimumab | Kromeya |  | 2019-04-02 |  |  | |
| Tocilizumab | Tyenne |  | 2023-09-15 |  |  | |
| Hisamitsu Pharmaceutical | Menthol, Methyl salicylate | Salonpas | 2027-08-01 | 2008-02-20 |  |  |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
85%17/20
Phase 2
43%9/21
Phase 3
39%11/28
Approved: 4Overall Success rate: 14%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use